Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.
Neoplasms|Head and Neck Neoplasms
DRUG: Oxaliplatin and Docetaxel
Response rate as determined by RECIST criteria every 6 weeks., 2 Years
Toxicity and Quality of Life assessments every 3 weeks., 2 years
Oxaliplatin: 130mg/m2 given on day 1 by intravenous injection; and Docetaxel: 60mg/m2 given on day 1 by intravenous injection

Cycles are repeated every 21 days until disease progression, unacceptable toxicity or subject's withdrawal.